Related Experiment Video
Updated: May 13, 2025
09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
222
Rate of Decrease in Serum Autotaxin Can Predict Relapse of Type 1 Autoimmune Pancreatitis After Initial Steroid
Ichitaro Horiuchi1, Akira Nakamura1, Yasuhiro Kuraishi1
1Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine.
Pancreas
|April 16, 2025
Summary
Predicting autoimmune pancreatitis (AIP) relapse is crucial. Combining IgG4 and autotaxin (ATX) decrease rates after steroid therapy shows promise for identifying patients at risk of AIP relapse.
Area of Science:
- Immunology
- Gastroenterology
- Biochemistry
Background:
- Autoimmune pancreatitis (AIP) relapse is a significant clinical concern.
- Serum autotaxin (ATX) has emerged as a potential biomarker for AIP.
- Predictive markers for AIP relapse are needed to guide treatment strategies.
Purpose of the Study:
- To investigate the utility of serum IgG4 and ATX levels in predicting relapse in patients with autoimmune pancreatitis.
- To analyze the changes in serum IgG4 and ATX levels following steroid therapy.
Main Methods:
- Retrospective analysis of 37 autoimmune pancreatitis patients who received initial steroid therapy.
- Measurement of serum IgG4 and autotaxin (ATX) levels before and after treatment.
- Calculation of the rates of decrease (Δ) for serum IgG4 and ATX.
Main Results:
- No significant difference in the decrease rate of serum IgG4 between nonrelapse and relapse groups (P =0.12).
- A statistically significant difference was observed in the decrease rate of serum ATX between the groups (P <0.01).
- A combined positive predictive value of 86.5% for relapse was achieved using the decrease rates of both IgG4 and ATX.
Conclusions:
- The rate of decrease in serum ATX levels after steroid therapy is a significant predictor of relapse in autoimmune pancreatitis.
- Combining the decrease rates of serum IgG4 and ATX offers a valuable tool for predicting relapse in AIP patients.
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
56
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
56
01:29Chronic Pancreatitis II: Collaborative Care
50
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
50
01:30Acute Pancreatitis II: Clinical Manifestations and Management
72
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
72
01:17Gastritis-II: Pathophysiology
176
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
176
01:27Acute Pancreatitis I: Introduction
264
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
264
01:16Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127